Research Analysts’ Weekly Ratings Changes for Enliven Therapeutics (ELVN)

Enliven Therapeutics (NASDAQ: ELVN) recently received a number of ratings updates from brokerages and research firms:

• 10/19/2026 – Enliven Therapeutics had its price target raised by HC Wainwright from $65.00 to $73.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Enliven Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/13/2026 – Enliven Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/8/2026 – Enliven Therapeutics had its “buy” rating reaffirmed by Guggenheim.
• 10/2/2026 – Enliven Therapeutics is now covered by Morgan Stanley. They set an “overweight” rating and a $70.00 price target on the stock.
• 10/1/2026 – Enliven Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $75.00 price target on the stock.

Insider Buying and Selling at Enliven Therapeutics

In related news, Director J. Scott Garland sold 13,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director directly owned 13,000 shares in the company, valued at approximately $606,710. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $38.48, for a total value of $231,572.64. Following the completion of the sale, the chief financial officer owned 38,000 shares in the company, valued at $1,462,240. This represents a 13.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 189,849 shares of company stock worth $11,054,870 over the last ninety days. 3.00% of the stock is currently owned by corporate insiders.

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.